" class="no-js "lang="en-US"> Ferrer Launches Third Edition of Ferrer 4 Future (F4F) Program - Medtech Alert
Wednesday, May 22, 2024

Ferrer Launches Third Edition of Ferrer 4 Future (F4F) Program

Ferrer, a privately-held Spanish pharmaceutical company who aims to make a positive impact in society, today announces its continued commitment to digital health with the third edition of its innovation program Ferrer 4 Future (F4F). The open innovation program aims to empower entrepreneurs and digital health businesses, to develop disruptive health solutions – using digital technology. Participating start-ups can propose digital healthcare solutions, using new technologies, against the latest challenges set by Ferrer, via an online platform.

The purpose of the F4F program is the co-development of technology-based healthcare solutions, between start-ups and Ferrer. The collaboration begins with a careful selection process of proposed solutions, against two challenges posed by Ferrer. Following an initial scoring process, the start-ups present and defend their solutions before the start-up advisory board, who then pick the winner. The winning start-up participates in the program, which includes the possibility of piloting the solution on a real life case study and holds the potential to explore commercial alliances and collaborations with Ferrer in the future. The collaboration agreements are customized – according to the nature and maturity of each project. The duration of the co-development varies between 3 and 18 months, during which time, access to Ferrer mentors and experts, combined with access to internal resources, is guaranteed, and speeds up the creation of the solution.

“Through this innovative program, we embrace the collaborative path to promote future projects with value, for patients and stakeholders alike within the healthcare system,” said Tatjana Naranda, Ferrer’s Chief R&D Officer. “We believe in the key role that digital health plays in the present and will play in the future when it comes to building a more efficient healthcare system – one that is accessible to all sectors of the population.”

Ferrer’s F4F 2021 program offers two challenges to participating start-ups:

  • Challenge 1: Is there a digital solution that may help screen people with mild cognitive impairment and distinguish if there is a pathological evolution in cognitive functions, to allow long-term monitoring of the disease and provide the appropriate treatment?
  • Challenge 2: Is there an easy-to-use digital solution to maximise independence in the daily tasks of patients living with mild cognitive impairment, through personalized cognitive or motor rehabilitation?

The challenges require patient-centric solutions which facilitate the daily activity of healthcare professionals who are supporting patients with neurological disorders, whilst in primary healthcare settings or specialized neurology clinics, as they care for people with mild cognitive impairment. The solutions should also provide the healthcare professionals with precise follow-up tools and features.

“The empowerment of patients and doctors with digital health tools to address some of the concerns around cost, equity and access to healthcare is aligned with the company’s vision and the purpose of Ferrer‘s digital health department; to build a healthier society through digital technologies and contribute to the sustainability of healthcare systems”, added Gemma Estrada, Head of Digital Health in Ferrer. 

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more